Arcadia Biosciences, Inc.: 10-Q filed 2025-05-08
What Arcadia Biosciences, Inc. reported in its quarterly report filed 2025-05-08 (fiscal Q1 2025): 38 published measures, 80 facts as tagged in accession 0000950170-25-066425.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2025-05-08
- Fiscal period
- fiscal Q1 2025
- Accession
- 0000950170-25-066425 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Arcadia Biosciences, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 12,990,000 | USD | |
| At 2024-12-31 | 13,517,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 4,085,000 | USD | |
| At 2024-12-31 | 7,294,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 3,159,000 | USD | |
| At 2024-12-31 | 4,242,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 2,599,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -2,423,000 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | -1,588,000 | USD | 90 |
| 2024-01-01 to 2024-12-31 | -9,600,000 | USD | 366 |
| 2024-01-01 to 2024-03-31 | -3,210,000 | USD | 91 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 0 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 13,000 | USD | 91 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 1,200,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 987,000 | USD | 91 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 5,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 5,000 | USD | 91 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 500,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 4,000 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | -276,279,000 | USD | |
| At 2024-12-31 | -278,878,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 1,366,060 | shares | 90 |
| 2024-01-01 to 2024-03-31 | 1,361,657 | shares | 91 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 1,366,203 | shares | 90 |
| 2024-01-01 to 2024-03-31 | 1,361,657 | shares | 91 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 1.9 | USD/shares | 90 |
| 2024-01-01 to 2024-03-31 | -1.78 | USD/shares | 91 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 1.9 | USD/shares | 90 |
| 2024-01-01 to 2024-03-31 | -1.78 | USD/shares | 91 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 28,000 | USD | |
| At 2024-12-31 | 41,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 78,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 138,000 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 530,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -1,588,000 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 8,846,000 | USD | |
| At 2024-12-31 | 9,242,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 2,216,000 | USD | |
| At 2024-12-31 | 2,563,000 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 1,285,000 | USD | |
| At 2024-12-31 | 904,000 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 1,738,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 2,062,000 | USD | 91 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 0 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 6,000 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 1,367,040 | shares | |
| At 2024-12-31 | 1,364,940 | shares |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 8,905,000 | USD | |
| At 2024-12-31 | 6,223,000 | USD | |
| At 2024-03-31 | 10,483,000 | USD | |
| At 2023-12-31 | 12,703,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 19,000 | USD | |
| At 2024-12-31 | 137,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 21,000 | USD | |
| At 2024-12-31 | 155,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 1,907,000 | USD | |
| At 2024-12-31 | 1,907,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 1,879,000 | USD | |
| At 2024-12-31 | 1,866,000 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 39,000 | USD | |
| At 2024-12-31 | 39,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 92,000 | USD | |
| At 2024-12-31 | 92,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 1,000,000 | USD | |
| At 2024-12-31 | 2,000,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2025-03-31 | 727,000 | USD | |
| At 2024-12-31 | 931,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 2,599,000 | USD | 90 |
| 2024-01-01 to 2024-12-31 | -7,000,000 | USD | 366 |
| 2024-01-01 to 2024-03-31 | -2,423,000 | USD | 91 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 2,599,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -2,363,000 | USD | 91 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 13,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 51,000 | USD | 91 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 0 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 3,000 | USD | 91 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 193,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | 246,000 | USD | 91 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2025-01-01 to 2025-03-31 | 381,000 | USD | 90 |
| 2024-01-01 to 2024-03-31 | -303,000 | USD | 91 |
Inspect the source
- Entity
- Arcadia Biosciences, Inc. / CIK 0001469443
- Captured
- 2026-09-20T09:07:21.204Z
- SEC response SHA-256
f806f5e943ca77a8b894ab622b0441684ca24fc4c2b017f1608fffb332b90f9d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001469443.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))